Product Description
Mechanisms of Action: NRI,SRI,DRI
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: NeuroSearch A/S
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Alzheimer Disease|Obesity|Weight Loss|Parkinson's Disease|Type 2 Diabetes|Prader-Willi Syndrome
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-003672-12 | P2 |
Completed |
Obesity |
2020-10-16 |
|
| TM005 | P2 |
Completed |
Obesity |
2020-10-16 |
|
| 2016-003694-18 | P2 |
Completed |
Prader-Willi Syndrome |
2019-07-22 |
|
| 2016-003694-18 | P2 |
Completed |
Prader-Willi Syndrome |
2019-07-22 |